Lung Foundation New Zealand Tuapapa Pukahukahu Aotearoa understands there are many pressures on government (Pharmac too), especially in 2022. We acknowledge and support the philosophy the government has employed with its response to covid and reducing the impacts of covid, which is informed by scientific evidence and well-being; dedicated to reducing the burden on the […]
Analysis of Cancer Medicine Availability in Aotearoa by Te Aho o Te Kahu
While we acknowledge Te Aho o Te Kahu for publishing this report, it is merely telling us what we already know. Notable is the timing of this report which well follows the review of Pharmac (and prior to that the flawed health system review..). Till now Te Aho o Te Kahu hasn’t acknowledged the huge […]
Lung Foundation NZ acknowledges decision to fund durvalumab
Pharmac’s decision to fund immunotherapy treatment durvalumab (imfinzi) for stage 3 lung cancer is a small step forward. Lung Foundation New Zealand (LFNZ) acknowledges the leaders and clinical advisors at Pharmac and the key people at AstraZeneca for getting durvalumab (imfinzi) across the line. This funding decision also highlights extreme inequities with access to treatments […]
Respiratory Research Review Features Lung Cancer
Lung Foundation New Zealand (LFNZ) really values the collaboration our cause has with Research Review. We’re pleased to publish the latest issue of Respiratory Research Review which focuses on Lung Cancer. Respiratory_Research_Review_Issue_193_Lung_Cancer
New research to focus on inequity in lung cancer
While, Lung Foundation New Zealand (LFNZ) endorses the funding decision and we applaud the efforts of the researchers that dedicate their life to improving health policy, providing lung cancer patients access to more treatment options NOW, will prevent premature death and eliminate inequities. https://www.rnz.co.nz/news/national/459893/new-research-fund-to-focus-on-inequity-in-lung-cancer-treatment-diagnosis
Pharmac Interim Report Provides Glimmer of Hope for Meaningful Change
We are pleased to share with you Lung Foundation New Zealand’s response to the Pharmac Interim Report. Our response is informed by patients, carers and healthcare professionals associated with our cause. We look forward to contributing to the next phase of the review. 2021 December – Lung Foundation New Zealand response to Interim Report per […]
November is Lung Cancer Awareness Month!
Help raise awareness about The Symptoms of Lung Cancer by sharing our BREATHE poster LFNZ-BREATHE-Symptoms-Poster Help raise awareness about Lung Cancer Risk Factors by sharing our Risk Factors poster Risk If you know someone that has been diagnosed with lung cancer, share our patient introductory letter C005895-Patient-information-A4-1 Donate to help support our advocacy and patient […]
Further Submission To The Pharmac Review Committee
Following Lung Foundation New Zealand’s (LFNZ) participation in the patient group meeting hosted by The Pharmac Review Committee on 16th July in Wellington, we have taken the opportunity to provide a further submission. We so respect this/our very brave patient, for highlighting the terrible inequity lung cancer patients are faced with in NZ. LFNZ has […]
Submission to the Pharmac Review
Lung Foundation New Zealand (LFNZ) filed a submission (link below) to the pharmac review committee and participated in the review forum held at the Ministry of Health in Wellington alongside many other patients groups. LFNZ has collaborated with other advocacy groups to provide the review committee with insights into the experiences of patients and too […]
The First Lung Cancer Quality Improvement Report by Te Aho o Te Kahu, Cancer Control Agency
It is acknowledged The Lung Cancer Quality Report aims to provide information to help District Health Boards deliver consistent, high-quality cancer care. We too understand the purpose of the report is to analyse data from District Health Boards (DHBs) against eight quality performance indicators (QPIs) to identify disparities in care and variation in outcomes. Whilst […]